VG Life Sciences Inc. reported details of the successful completion of the first stage of its Phase I Trial to treat ovarian cancer. The study examines the safety and efficacy of one of VG Life Sciences' MDT compounds, hydroxychloroquine (HCQ), in combination with an existing cancer drug, sorafenib (marketed as Nexavar(TM)), which was co-developed by Bayer AG and Onyx Pharmaceuticals. Effective treatment options are urgently needed for patients suffering from ovarian cancer and are excited to have achieved the safety results expected from first set of patients.

As detailed in press release of July 19, 2012, there are three phases of this safety and efficacy study. The first stage, just completed, focused on the safety dosages, and all indications came in exactly as expected when designing the protocol. Patient safety is paramount throughout this level of study, and Phase II trials cannot commence, unless acceptable levels of safety are revealed in Phase I. These just completed results enable the Trial's primary investigator, Dr. Tyler Curiel, to proceed to the second set of patients, the screening for which has already commenced.

Upon successful completion of the second stage of testing, a third group of patients will be enrolled. A total of four sets of patients (stages) will be studied, each of which will have up to 6 patients. Presuming low levels of toxicity following dosing, additional patients will be added and higher doses of the combination will be given up to a pre-specified maximum dosage level.